Evidence map›Paper›PMID 38355621›Full record

ArticleAntimicrobial resistance and infection control2024

Prevalence, regional distribution, and trends of antimicrobial resistance among female outpatients with urine Klebsiella spp. isolates: a multicenter evaluation in the United States between 2011 and 2019.

Keith S Kaye, Vikas Gupta, Aruni Mulgirigama, Ashish V Joshi, Gang Ye, Nicole E Scangarella-Oman, Kalvin Yu, Fanny S Mitrani-Gold

Open access · goldAbstract readMulticenter Study
In one paragraph

Article in Antimicrobial resistance and infection control, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Incidence of carbapenemase-resistant isolates ofNew microbes and new infections · 2026
    Article
  3. Carbapenem-resistantbioRxiv : the preprint server for biology · 2026
    Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Keith S KayeDivision of Allergy, Immunology and Infectious Diseases, Rutgers - Robert Wood Johnson Medical School, New Brunswick, NJ, USA.
Vikas Gupta *MMS Medical Affairs, Becton, Dickinson and Company, Franklin Lakes, NJ, USA.
Aruni MulgirigamaAntibiotics, GSK, Brentford, London, UK.
Ashish V JoshiValue Evidence and Outcomes, GSK, Collegeville, PA, USA.
Gang Ye *Software Technology Solutions, Becton, Dickinson and Company, Franklin Lakes, NJ, USA.
Nicole E Scangarella-OmanDiagnostics and Clinical Microbiology, GSK, Collegeville, PA, USA.
Kalvin YuMedical and Scientific Affairs, Becton, Dickinson and Company, Franklin Lakes, NJ, USA.
Fanny S Mitrani-GoldEpidemiology, GSK, Collegeville, PA, USA. fanny.s.mitrani-gold@gsk.com.
Becton Dickinson (United States) · USGlaxoSmithKline (United States) · USRutgers, The State University of New Jersey · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAntimicrobial resistance research in uncomplicated urinary tract infection typically focuses on the main causative pathogen, Escherichia coli; however, little is known about the antimicrobial resistance burden of Klebsiella species, which can also cause uncomplicated urinary tract infections. This retrospective cohort study assessed the prevalence and geographic distribution of antimicrobial resistance among Klebsiella species and antimicrobial resistance trends for K. pneumoniae in the United States (2011-2019).

methodsK. pneumoniae and K. oxytoca urine isolates (30-day, non-duplicate) among female outpatients (aged ≥ 12 years) with presumed uUTI at 304 centers in the United States were classified by resistance phenotype(s): not susceptible to nitrofurantoin, trimethoprim/sulfamethoxazole, or fluoroquinolone, extended-spectrum β-lactamase-positive/not susceptible; and multidrug-resistant based on ≥ 2 and ≥ 3 resistance phenotypes. Antimicrobial resistance prevalence by census division and age, as well as antimicrobial resistance trends over time for Klebsiella species, were assessed using generalized estimating equations.

results270,552 Klebsiella species isolates were evaluated (250,719 K. pneumoniae; 19,833 K. oxytoca). The most frequent resistance phenotypes in 2019 were nitrofurantoin not susceptible (Klebsiella species: 54.0%; K. pneumoniae: 57.3%; K. oxytoca: 15.1%) and trimethoprim/sulfamethoxazole not susceptible (Klebsiella species: 10.4%; K. pneumoniae: 10.6%; K. oxytoca: 8.6%). Extended-spectrum β-lactamase-positive/not susceptible prevalence was 5.4%, 5.3%, and 6.8%, respectively. K. pneumoniae resistance phenotype prevalence varied (p < 0.0001) geographically and by age, and increased over time (except for the nitrofurantoin not susceptible phenotype, which was stable and > 50% throughout).

conclusionsThere is a high antimicrobial resistance prevalence and increasing antimicrobial resistance trends among K. pneumoniae isolates from female outpatients in the United States with presumed uncomplicated urinary tract infection. Awareness of K. pneumoniae antimicrobial resistance helps to optimize empiric uncomplicated urinary tract infection treatment.

Indexed as

KlebsiellaUrinary Tract InfectionsAnti-Bacterial Agentsbeta-LactamasesDrug Resistance, BacterialEscherichia coliFemaleHumansKlebsiella pneumoniaeNitrofurantoinOutpatientsPrevalenceRetrospective StudiesTrimethoprim, Sulfamethoxazole Drug CombinationUnited StatesAnti-Bacterial Agentsbeta-LactamasesNitrofurantoinTrimethoprim, Sulfamethoxazole Drug CombinationAntimicrobial resistanceKlebsiella oxytocaKlebsiella pneumoniaeUncomplicated urinary tract infection

Identifiers

PMID38355621
PMCPMC10865585
OpenAlexW4391822070

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.